MERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien Q3 2026 Earnings Recap

MRK.DE Q3 2026 Published November 14, 2026

Get alerts when MRK.DE reports next quarter

Set up alerts — free

Merck reported 5.1% organic sales growth in Q3 and raised full-year guidance; the shares fell 1.3%, a roughly flat reaction. Growth in Life Science and Electronics was tempered by accelerating Mavenclad erosion in U.S. Specialty Care and expected further headwinds in consumer electronics.

Earnings Per Share Beat
$2.37 vs $2.23 est.
+6.3% surprise
Revenue Beat
5743841000 vs 5476497000 est.
+4.9% surprise

Market Reaction

Post-Earnings -1.32%

See MRK.DE alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • Group organic sales growth accelerated to 5.1%, with significant contributions from Life Science and Electronics.
  • Life Science’s Process Solutions grew 10.5% organically; Discovery Solutions recorded modest growth as markets stabilized.
  • Electronics organic growth reached 13%, led by Semiconductor Solutions at 19%; Optronics was broadly stable, with consumer electronics headwinds expected to intensify.
  • Healthcare sales improved sequentially. Rare Diseases contributed to organic growth for the first time, while Specialty Care faced faster U.S. Mavenclad erosion.
  • Management raised full-year guidance again and cited strong cash generation and an improved leverage ratio; the transcript excerpt does not provide the updated guidance figures.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MRK.DE on AllInvestView.

Get the Full Picture on MRK.DE

Track MERCK Kommanditgesellschaft auf Aktien in your portfolio with real-time analytics, dividend tracking, and more.

View MRK.DE Analysis